ESMO 2021 Industry Satellite Symposium

Join us for the symposium Friday, September 17, 2021 08:45–10:15 (CEST) - Channel 5

The clinical value of mIDH1 inhibition in cholangiocarcinoma

Isocitric dehydrogenase: an actionable genetic alteration in cholangiocarcinoma Angela Lamarca (UK)

The scientific rationale for mIDH1 inhibition **Juan Valle** (UK)

Clinical evaluation of mIDH1 inhibition **Rachna T. Shroff** (USA)

Discussion on the clinical value of mIDH inhibition Arndt Vogel (Germany) & Angela Lamarca (UK)

Identifying patients with mIDH1: how and when to do molecular testing
Teresa Macarulla (Spain)

What does all this mean for a patient with cholangiocarcinoma? **Arndt Vogel** (Germany)

Live Q&A and Discussion Angela Lamarca (UK) Teresa Macarulla (Spain) Rachna T. Shroff (USA) Juan Valle (UK) Arndt Vogel (Germany)



Chairs: A. Lamarca (UK) A. Vogel (Germany)

Organized by